BellWR, SimonTL. Current status of pulmonary thromboembolic disease: Pathophysiology, diagnosis, prevention, and treatment. Am Heart J1982;103:239–262.
2.
FreimanDG, SuyemotoJ, WesslerS.Frequency of pulmonary thromboembolism in man. N Engl J Med1965;272:1278–1280.
3.
SasaharaAA, SharmaGVRK, BarsamianEM, SchoolmanM, CellaG.Pulmonary thromboembolism: Diagnosis and treatment. JAMA1983;249:2945–2950.
4.
SalzmanEW, DeykinD, ShapiroRM, RosenbergR.Management of heparin therapy: Controlled prospective trial. N Engl J Med1975;292:1046–1051.
5.
CoonWW, WillisPW, SymonsMJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg1969;170:559–567.
6.
The urokinase pulmonary embolism trial: A national cooperative study. Circulation1973;47 (Suppl 2):II-1–II-108.
SasaharaAA, SharmaGVRK, TowDE, McIntyreKM, ParisiAF, CellaG.Clinical use of thrombolytic agents in venous thromboembolism. Arch Intern Med1982;142:684–688.
9.
Thrombolytic therapy in thrombosis. NIH Consensus Dev Conf Summ1980;3:1–6.
10.
UtsunomiyaT, KrauszMM, LevineL, SheproD, HechtmanHB. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest1982;70:361–368.
11.
PuckettCL, GervinAS, RhodesGR, SilverD.Role of platelets and 5-HT in acute massive pulmonary embolism. Surg Gynecol Obstet1973;137:618–622.
12.
RosoffCB, SalzmanEW, GurewichV.Reduction of platelet 5-HT and the response to pulmonary emboli. Surgery1971;70:12–19.
13.
ThomasDP, GurewichV, AshfordTP. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. N Engl J Med1966;275:953–958.
HuvalWV, MathiesonMA, StempLI, DunhamBM, JonesAG, SheproD, HechtmanHB. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Ann Surg1983;197:220–225.
16.
LeysenJE, AwoutersF, KennisL, LaduronPM, VanderberkJ, JansenPAJ. Receptor binding profile of R 41, 468, a novel antagonist of 5-HT2 receptors. Life Sci1981;28:1015–1022.
